Arcutis Biotherapeutics (NASDAQ:ARQT) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of Arcutis Biotherapeutics (NASDAQ:ARQTGet Rating) from a sell rating to a hold rating in a research report sent to investors on Monday, Zacks.com reports.

According to Zacks, “Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company’s product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California. “

A number of other analysts have also recently commented on ARQT. Morgan Stanley lifted their price target on Arcutis Biotherapeutics from $35.00 to $37.00 and gave the stock an overweight rating in a research report on Wednesday, March 2nd. The Goldman Sachs Group began coverage on Arcutis Biotherapeutics in a research report on Thursday, March 17th. They set a buy rating and a $45.00 price target for the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Arcutis Biotherapeutics in a research report on Wednesday, February 23rd. Finally, Mizuho lowered their price target on Arcutis Biotherapeutics from $58.00 to $57.00 and set a buy rating for the company in a research report on Thursday, April 7th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Buy and an average target price of $41.50.

Shares of ARQT stock opened at $21.34 on Monday. Arcutis Biotherapeutics has a 1-year low of $13.59 and a 1-year high of $35.49. The stock’s fifty day simple moving average is $18.75. The company has a current ratio of 12.09, a quick ratio of 12.09 and a debt-to-equity ratio of 0.24. The stock has a market cap of $1.10 billion, a P/E ratio of -5.13 and a beta of 0.36.

Arcutis Biotherapeutics (NASDAQ:ARQTGet Rating) last announced its earnings results on Tuesday, February 22nd. The company reported ($1.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.41) by ($0.01). Sell-side analysts predict that Arcutis Biotherapeutics will post -5.51 EPS for the current year.

In related news, insider David W. Osborne sold 2,197 shares of Arcutis Biotherapeutics stock in a transaction dated Thursday, April 21st. The stock was sold at an average price of $20.42, for a total value of $44,862.74. Following the completion of the transaction, the insider now owns 257,229 shares in the company, valued at approximately $5,252,616.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Todd Franklin Watanabe sold 2,489 shares of Arcutis Biotherapeutics stock in a transaction dated Friday, March 4th. The shares were sold at an average price of $16.86, for a total value of $41,964.54. The disclosure for this sale can be found here. In the last three months, insiders sold 550,767 shares of company stock valued at $11,368,506. Insiders own 39.00% of the company’s stock.

Several institutional investors have recently made changes to their positions in ARQT. Point72 Asset Management L.P. increased its stake in shares of Arcutis Biotherapeutics by 122.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,992,107 shares of the company’s stock valued at $47,591,000 after purchasing an additional 1,095,707 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Arcutis Biotherapeutics in the 4th quarter valued at about $12,809,000. Norges Bank purchased a new stake in Arcutis Biotherapeutics during the 4th quarter worth approximately $5,504,000. BlackRock Inc. increased its stake in Arcutis Biotherapeutics by 2.8% during the 4th quarter. BlackRock Inc. now owns 4,313,864 shares of the company’s stock worth $89,471,000 after buying an additional 117,938 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Arcutis Biotherapeutics by 29.5% during the 4th quarter. American Century Companies Inc. now owns 487,071 shares of the company’s stock worth $10,102,000 after buying an additional 110,997 shares in the last quarter. Hedge funds and other institutional investors own 87.59% of the company’s stock.

About Arcutis Biotherapeutics (Get Rating)

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

Read More

Get a free copy of the Zacks research report on Arcutis Biotherapeutics (ARQT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arcutis Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcutis Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.